-+ 0.00%
-+ 0.00%
-+ 0.00%

Longeveron Announces Data From Phase 2b Clinical Study Of Stem Cell Therapy Demonstrates Improved Conditions Of Participants With Aging-Related Frailty, Meaningful Increase In Primary Endpoint Of 6-Minute Walk Test

Benzinga·02/25/2026 16:12:06
Listen to the news

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

Laromestrocel (LOMECEL-B®) is a proprietary, scalable, allogeneic stem cell (MSC) investigational therapy that is currently being evaluated in multiple indications.

The Phase 2b, randomized, dose-finding clinical trial evaluated whether laromestrocel, human bone marrow-derived allogeneic MSCs, improves physical functioning and patient self-reported outcomes in 148 ambulatory individuals with frailty (NCT03169231).